Historical Press Releases:
The press releases posted on this Site are current only as of their
date. Nventa Biopharmaceuticals does not update its press releases solely due to
a change in the facts described in old press releases. Old press
releases are provided only to give readers a sense of past developments
and should not be taken as implying that the information contained
in them remains accurate.
Press Releases 2000
  Dec
21 2000 - StressGen Announces New Director of Clinical Operations
and Other Senior Management Changes -- Clinical and R&D Team Expanded
as Company Advances into Phase III Trials
Nov
14 2000 - StressGen Announces Ruling in European Patent Opposition
Proceedings
Nov
14 2000 - StressGen Reports Third Quarter Financial Results
- Underwriters exercise their over-allotment option
Nov
8 2000 - StressGen Scientists and Key MIT Collaborators Present
at International Symposium on Heat Shock Proteins in Biology and
Medicine
- Data Reinforces Utility of Heat Shock Protein Fusions as Platform
for Development of Novel Immunotherapeutics
Nov
6 2000 - StressGen Initiates HSPE7 Phase III Trial in HPV-Related
Anal Dysplasia
- CDC reports HPV second only to HIV in US STD related healthcare
costs
Oct
24 2000 - StressGen Added to the TSE 300 Composite Index
Oct
17 2000 - StressGen Closes CDN$45.5 million Public Offering
Oct
10 2000 - StressGen Files Final Prospectus for $45.5 million Public
Offering
Oct
3 2000 - StressGen Presents Early Data Indicating 75% of Patients
Convert from High Grade to Low Grade Dysplasia - HspE7 May Treat
Disease of Multiple HPV Types including Genital Warts Types
Sept
20 2000 - StressGen Announces Public Offering
Sept
6 2000 - StressGen Initiates HSPE7 Phase II Trial in Cervical Cancer
- Heat Shock Fusion Protein - A Novel Therapeutic for HPV-Related
Diseases
Aug
21 2000 - StressGen Reports Data on Recombinent Fusion Protein HSPE7
Mechanism of Action
- Clin. Exp. Immunol. Paper Also Highlights Potential Novel Therapeutic
Approach for Immunocompromised Patient Population
July
26 2000 - StressGen Presents Positive Clinical Data at 18th International
Papillomavirus Conference
- HspE7: A Novel Heat Shock Protein Fusion for HPV-Related Diseases
June
27 2000 - Positive Clinical Data Advances Stressgen's HSPE7 to Phase
III in Anal Dysplasia
June
13 2000 - Stressgen Receives $5.75 million from Exercise of Warrants
May
29 2000 - Stressgen Announces Appointments to Board of Directors
May
22 2000 - StressGen Reports Fusion Protein Drug for Human Papillomavirus
Demonstrated Positive Immune Responses and is Well Tolerated in
Phase I Study
May
17 2000 - StressGen announces 2000 first quarter results
May
1 2000 - StressGen Receives Proceeds from Special Warrant Financing
Following Clearance of Final Prospectus
Mar
16 2000 - StressGen Biotechnologies Announces Initiation of Phase
II Study with HspE7
Mar
10 2000 - StressGen Announces Filing of Preliminary Prospectus
Mar
9 2000 StressGen Announces Fourth Quarter and Fiscal Year-end 1999
Results
Feb
16 2000 - StressGen to Present at 2nd Annual BIO CEO & Investor
Conference
Feb
2 2000 - StressGen completes special warrant financing raising $25,326,600
Jan
20 2000 - StressGen announces $25.3 million special warrant financing
Jan
17 2000 - Whitehead Institute/MIT Study Suggests StressGen's Stress
Proteins May Play Key Role in Treating Immunocompromised Populations
Jan
10 2000 - StressGen Introduces New Hsp70 Immunoassay Kit for Researchers
|
